MOTS-c injections in obese mice lowered sebacate, a dicarboxylic acid, by 42% compared to untreated mice.

Scientific Claim

In diet-induced obese mice, MOTS-c injection was associated with a 42% reduction in plasma sebacate levels (fold change 0.58, P = 0.0464; n=6 per group).

Original Statement

“Sebacate (decanedioate)** (P = 0.0464; fold change = 0.58)”

From study:The mitochondrial‐derived peptide MOTS‐c is a regulator of plasma metabolites and enhances insulin sensitivity

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study design allows for association claims between treatment and outcome, but lacks randomization and blinding, so causal language is inappropriate. 'Associated with' correctly reflects the evidence.

Evidence from Studies

Supporting (1)

The mitochondrial‐derived peptide MOTS‐c is a regulator of plasma metabolites and enhances insulin sensitivity

Cohort Study

Animal

2019 Jul

Contradicting (0)

No contradicting evidence found

Source Study

The mitochondrial‐derived peptide MOTS‐c is a regulator of plasma metabolites and enhances insulin sensitivity

Score: 8

DOI: 10.14814/phy2.14171

Similar Assertions

Obese mice given MOTS-c had lower levels of suberate, a dicarboxylic acid, by 40% compared to untreated mice.

90%

MOTS-c injections in obese mice reduced a type of fat molecule called 2-oleoylglycerol by about 32% compared to untreated mice.

82%

Obese mice given MOTS-c injections for three days had lower blood sugar levels than mice that didn't receive the treatment.

78%

MOTS-c injections in obese mice lowered a specific blood fat molecule called sphingosine 1-phosphate by about 14% compared to untreated mice.

76%

Obese mice treated with MOTS-c had lower levels of a specific sphingolipid called palmitoyl sphingomyelin, which is associated with insulin resistance.

75%